Arena Pharmaceuticals — Investor Presentation (January 2019)
37 slides from Arena Pharmaceuticals's investor presentation, Jan 7, 2019
Slide 1: Corporate Presentation
Corporate Presentation Nasdaq: ARNA January 2019 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about the Arena investment thesis, catalysts, value, our investigative stage drug candidates, including with respect to their potential (including to become first or best-in-c
Slide 3: Investment Highlights and 2019 Catalysts
Etrasimod with $4-8B market potential - best-in-class S1P selectivity and clinical control Broad pipeline with additional Ph 2 programs including etrasimod (derm) and olorinab (GI pain) Recently announced positive OLE data for etrasimod Announced ralinepag deal provides strong cash position ~$1.3B p
Slide 4: Deep Pipeline with Therapeutic Focus
Ralinepag Potent IP Receptor Agonist PAH - Time to Clinical Events Ph 3 Initiated PAH – Ex Capacity 6MWD Ph 3 PAH – Ex Capacity CPET Ph 3 PAH - Differentiation 1H:19 Initiation APD418 Calcium-Independent Myofilament Derepressor Decompensated heart failure (DHF) IND 2019 Deep Pipeline with Therapeuti
Slide 5: Etrasimod
Oral, Next Generation, S1P Receptor Modulator with Optimized Activity Being Evaluated for Multiple Immune and Inflammatory-Mediated Etrasimod
Slide 6: Etrasimod - Next-Generation and Best-in-Class S1P Receptor Modulator
Source: 1UC & CD Disease Landscape & Forecast Reports. DRG. 2018. 2The Facts About IBDs. Crohn’s & Colitis Foundation of America. 2014. 3European Population IBD Prevalence. European Crohn’s and Colitis Organization website viewed Sep 2016. 4Hirten RP, et al. Clin Gastroenterol Hepatol. 2018 Sep;16(9
Slide 7: Etrasimod Progressing Rapidly with Best-in-Class Profile
Well characterized, developed in-house Higher selectivity drives efficacy and safety Improved PD – rapid on-rate + rapid off-rate with true 36 hour half-life UC data supportive of category leading efficacy with good safety / tolerability Moving to Ph 3 in UC and Ph 2/3 in Crohn’s disease Moving aggr
Slide 8: GI Physicians Conjoint Study Shows Etrasimod Emerging as Potential Market Leader
Source: Arena data on file 100 GI Physicians Quantitative Conjoint Study Shows Etrasimod Emerging as Potential Market Leader in IBD Mod/Severe Patients Not Receiving Biologics Etrasimod vs. Ozanimod (Estimated Future Preference) Oral Market Increasing (Estimated Future Preference) S1P vs. JAK (Estim
Slide 9: S1P Modulation May Avoid Off-Target Activity
S1P Modulation May Avoid Off-Target Activity S1P = Sphingosine 1-phosphate; UC = ulcerative colitis. *Data generated at Arena or under sponsored research by Arena Etrasimod’s Highly Selective Etrasimod Decreased Inflammation & Improvement in Immune-Inflammatory Disorders Positive Outcome Negative Ou
Slide 10: Etrasimod Has a Quick Offset of Action
Ozanimod Similar to Gilenya; Etrasimod Only 2nd Generation Sources: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-996. 2-Kovarik JM et al, J Clin Pharmacol. 2004;44:535-537. 3- ADP334 P1 Data on File; *Active metabolite Etrasimod Has a Quick Offset of Action Note – Data Collected from Separate Stud
Slide 11: Etrasimod Has a Quick Onset of Action
Phase 1 Data *After dose escalation of ozanimod (0.3 mg/d on days 1–3; 0.6 mg/d on days 4 and 5; 1 mg/d on days 6 and 7; and 3 mg/d on days 8–10. Data truncated at day 11 (ozanimod) and 15 (etrasimod) to show on-treatment onset effects Sources: 1-Tran JQ et al, J Clin Pharmacol. 2017;57:988-996. 2-
Slide 12: Etrasimod Demonstrates Competitive Efficacy in UC
Source: Etrasimod: Post-hoc analysis. Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists.. Sources: Ozanimod: Sandborn, et al. NEJM 2016; Xeljanz: Sandborn, et al. NEJM 2017; Entyvio: Feagan, et al.
Slide 13: Phase 2 Safety Profile
Etrasimod was generally safe and well tolerated Adverse events were predominantly mild to moderate No serious adverse events (SAEs) at the 2 mg dose Impact on HR and AV conduction was low throughout the study with no discontinuations related to bradycardia or AV block. No SAEs related to HR changes
Slide 14: Etrasimod Demonstrated Long-Term Clinical Remission
Etrasimod Demonstrated Long-Term Clinical Remission 2 mg Treat-Through: Subjects who received 2 mg etrasimod throughout OASIS and the OLE Clinical Remission defined as Rectal Bleeding = 0; Endoscopic Improvement = 0,1; Stool Frequency = 0,1 (per FDA draft guidance 2016) (End of Treatment)
Slide 15: Consistent Lymphocyte Reduction and Improved Clinical Response
Etrasimod Demonstrated Consistent Lymphocyte Reduction and Improved Clinical Response Lymphocyte Reduction Clinical Response (n=34) (n=29) (n=29) (n=31) (n=31) (n=22)
Slide 16: Etrasimod OLE Safety and Tolerability
Etrasimod OLE Safety and Tolerability Etrasimod demonstrated a favorable long-term safety profile; adverse events were generally mild to moderate in severity Impact on heart rate and atrioventricular (AV) conduction was minimal throughout the study with no discontinuations from study related to brad
Slide 17: Advancing to Ph 3 in UC & Crohn's Disease
Δ=% difference from placebo estimated using Mantel-Haenszel method adjusted with current oral corticosteroid use and prior exposure to TNFα antagonists. Arena data on file. Advancing to Ph 3 in UC & Crohn’s Disease Ulcerative Colitis (UC) Optimize study design Bigger effect size Expedited trial desi
Slide 18: Ph 3 Program in UC Designed for Speed to Market
Ph 3 Program in UC Designed for Speed to Market Study 1 Adults Biologics/JAK inhibitor: 50% naïve 50% exposed Etrasimod, 2 mg Placebo Week 12 Week 52 Primary Endpoints Study 1: Week 52 clinical remission (modified Mayo Clinic score) Study 2: Week 12 clinical remission (modified Mayo Clinic score) Po
Slide 19: Focus on Exploring Atopic Dermatitis
Source: 1Atopic Dermatitis/Atopic Eczema. Disease Landscape & Forecast. DRG. August 2018. 2Silverberg, JI. Dermatol Clin. 2017 Jul;35(3):283-289. 3Barbarot S, et al. Allergy. 2018 Jun;73(6):1284-1293. 4Atopic Dermatitis: Survey of 192 Patients. National Eczema Association 2016. 5Egeberg A, et al. J
Slide 20: Etrasimod Potential to Impact Inflammatory Dermatological Diseases
DC – Dendritic Cells Etrasimod Has Potential to Impact Broad Range of Inflammatory Dermatological Diseases DC TH1 TH17 TH2 TH22 Epidermis Lymph Node T T Dermis T cell driven inflammation in multiple immune-mediated skin diseases Etrasimod may improve skin disease by inhibiting dendritic cell & T cel
Slide 21: Etrasimod Early Clinical Result in Pyoderma Gangrenosum
Etrasimod Early Clinical Result in Pyoderma Gangrenosum Baseline Image Initial Measurement (7/5/17) Current Image Date of Assessment (9/27/17) Initial Area (CmSq) Current Area (CmSq) Percent Area Change Length 4.668 1.520 -67.44% 2.18cm “Very impressed with the patient’s progress. Can the treatment
Slide 22: Olorinab
Peripherally Restricted, Highly–Selective, Full-Agonist to Cannabinoid 2 Receptor (CB2) for Gastrointestinal Pain Olorinab
Slide 23: Olorinab Potential Best-in-Class Profile
Source: 1 DRG: IBS Report (2015), 2The Facts About IBDs. Crohn’s & Colitis Foundation of America. 2014. 3Drossman DA, et al. J Clin Gastroenterol. 2009 Jul; 43(6): 541–550. 4Adelphi 2017. 5Hacker B, et al. P216. Presented at: Crohn’s & Colitis Congress; Jan. 19-20, 2018; Las Vegas, NV. 6Camilleri M,
Slide 24: Olorinab May Address Clear Unmet Need in GI Pain
Olorinab May Address Clear Unmet Need in GI Pain Sources: 1 DRG: IBS Report (2015), 2 IFFGD & UNC: Online Study, n=1,966 (2007), 3 Allergan: Global Impact Report (2018), 4 ZS Analysis (U.S. Census/Datamonitor), 5 CDC: MMWR Prevalence of IBD, n=33,672 (2016), 6 Arena market research, 7 Waljee, Eur J
Slide 25: Successful Ph 2a Study Results Inform Development Path
Successful Ph 2a Study Results Inform Development Path Olorinab trial results demonstrate meaningful efficacy in patients with Crohn’s disease experiencing abdominal pain Reductions in abdominal pain seen within first wk of treatment Statistically significant improvements in pain over 8 wks of treat
Slide 26: Shared Mechanisms in IBS and IBD Pain
1. Barbara et al., (2014) Curr Opin Gastroenterol 30:352-358; 2. Cremon et al., (2017) Alimentary Pharmacology and Therapeutics 45:909-922; 3. Dr. Lin Chang, unpublished data; 4. Spiller and Major (2016), Nat Rev Gastroenterol Hepatol 13(10):613-21; 5. Vivinus-Nebot et al., (2013) Gut 63:744-752 Sha
Slide 27: Olorinab Evidences Strong Pre-Clinical Efficacy in IBS Model
Arena data, study being performed by Stuart Brierley's group; Hughes et al., (2009) Gut 58,1333-1341. CVH, Chronic Visceral Hypersensitivity; olorinab given BID (days 24-28) Olorinab Evidences Strong Pre-Clinical Efficacy in IBS Model Vehicle (N=14) Vehicle (N=14) Healthy IBD-like IBS-like Colitis i
Slide 28: Strong Signal in Average Abdominal Pain Score and Responder Analysis
Strong Signal in Average Abdominal Pain Score (AAPS) and Responder Analysis AAPS Improvement -4.6 *=p<0.05; **=p<0.01 85% of patients improved at week 4 100% of patients improved at week 8 (Evaluable Population with ≥30% change from baseline in AAPS)
Slide 29: Ralinepag
Next-Generation, Oral, Selective Prostacyclin Receptor (IP) Agonist for Pulmonary Arterial Hypertension Ralinepag
Slide 30: Benefits of IV Prostacyclin in Once-a-Day Oral Therapy
Source: 1Pulmonary Hypertension. Disease Landscape & Forecast. DRG. November 2016. 2United Therapeutics November 2018. 3Coghlan JG, et al. Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47. 4Benza RL, et al. Chest. 2012 Aug;142(2):448-456. 5Burger CD, et al. J Manag Care Spec Pharm. 2018 Mar;24(3):291-302
Slide 31: Ralinepag Impressive PVR Improvement
*PVR, change in least squares mean from placebo; **Flolan: Barst et al NEJM 1996 Feb 1;334(5): 296-301 Ralinepag Impressive PVR Improvement Ralinepag (n=40) Placebo (n=40) Placebo (n=21) -20.1% -21% Flolan® (n=41) 9% -30%** 9.6% -29.8%* Note: No direct head-to-head data available - Caution advised w
Slide 32: APD418
First-in-Class Calcium-independent Myofilament Derepressor (CMD) for Decompensated Heart Failure (DHF) APD418
Slide 33: APD418 is First-in-Class for DHF with Novel MOA
Source: 1Heart Failure. Disease Landscape & Forecast. DRG. June 2018. 2Dharmarajan K, et al. BMJ. 2015 Feb 5;350:h411. 3Nielsen DV, et al. Anesthesiology. 2014 May;120(5):1098-108. APD418 is First-in-Class for DHF with Novel MOA 70% readmitted within 1 year2 20% increased mortality with each rehospi
Slide 34: Decompensated Heart Failure Patients Deserve Better and Safer Options
Mebazaa A, et al. Intensive Care med. 2011 Feb;37(2):290-301. Nielsen DV, et al. Anesthesiology. 2014 May;120(5):1098-108. Intensive Care Med (2011) 37:290-301. DOI 10.1007/s00134-010-2073-4 Decompensated Heart Failure Patients Deserve Better and Safer Therapeutic Options Known Issues with Inotropes
Slide 35: Increased Cardiac Performance and Improved Cardiac Safety
Increased Cardiac Performance Canine model. Arena data on file Improved Cardiac Function Without Hemodynamic Liability in Animals Supports Advancement Into Clinic Improved Cardiac Safety Cardiac Output (L/min) LV Ejection Fraction (%) Heart Rate (beats/min) Mean Aortic Pressure (mmHg)
Slide 36: Investment Highlights and 2019 Catalysts
Etrasimod with $4-8B market potential - best-in-class S1P selectivity and clinical control Broad pipeline with additional Ph 2 programs including etrasimod (derm) and olorinab (GI pain) Recently announced positive OLE data for etrasimod Announced ralinepag deal provides strong cash position ~$1.3B p
Slide 37: Thank you
Thank you Nasdaq: ARNA
Arena Pharmaceuticals — Investor Presentation (January 2019) on 6ix